The University of Chicago Header Logo

Connection

Arlene Chapman to Genotype

Back to Details
This is a "connection" page, showing publications Arlene Chapman has written about Genotype.
Arlene Chapman
Connection Strength
0.590
Genotype
  1. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores. CPT Pharmacometrics Syst Pharmacol. 2020 12; 9(12):678-685.
    View in: PubMed
    Score: 0.135
  2. Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. PLoS One. 2019; 14(9):e0221957.
    View in: PubMed
    Score: 0.125
  3. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight. 2020 08 06; 5(15).
    View in: PubMed
    Score: 0.033
  4. Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. Kidney360. 2020 Jul; 1(7):648-656.
    View in: PubMed
    Score: 0.033
  5. Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2019 06 07; 14(6):823-833.
    View in: PubMed
    Score: 0.030
  6. ß2 -Adrenergic Receptor Gene Affects the Heart Rate Response of ß-Blockers: Evidence From 3 Clinical Studies. J Clin Pharmacol. 2019 11; 59(11):1462-1470.
    View in: PubMed
    Score: 0.030
  7. Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to ß-Blockers. J Am Heart Assoc. 2018 02 24; 7(5).
    View in: PubMed
    Score: 0.028
  8. Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response. Circ Cardiovasc Genet. 2017 Jan; 10(1).
    View in: PubMed
    Score: 0.026
  9. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016 09; 27(9):2872-84.
    View in: PubMed
    Score: 0.024
  10. Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. PLoS One. 2013; 8(10):e76984.
    View in: PubMed
    Score: 0.021
  11. G protein receptor kinase 4 polymorphisms: ß-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension. 2012 Oct; 60(4):957-64.
    View in: PubMed
    Score: 0.019
  12. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension. 2012 Jun; 59(6):1204-11.
    View in: PubMed
    Score: 0.019
  13. Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. J Transl Med. 2012 Mar 22; 10:56.
    View in: PubMed
    Score: 0.019
  14. Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: the GERA study. Physiol Genomics. 2009 Sep 09; 39(1):56-60.
    View in: PubMed
    Score: 0.015
  15. Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens. 2005 Aug; 18(8):1077-83.
    View in: PubMed
    Score: 0.012
  16. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens. 2003 Oct; 16(10):834-9.
    View in: PubMed
    Score: 0.010
  17. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int. 2002 Nov; 62(5):1718-23.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.